Correlation between hematopoietic immune function and prognosis of acute myeloid leukemia

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045808

Enrollment

Unknown

Registered

2021-04-25

Start date

2021-06-01

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18-60 years, KPS score > 60, estimated survival > 3 months; 2.No serious impairment of vital organs; 3.Voluntary subjects,and sign an informed consent; 4.Newly diagnosed patients with acute myeloid leukemia(Excluding APL).

Exclusion criteria

Exclusion criteria: 1.Patients combined with other malignant tumors. 2.Patients whose necessary treatment plan and follow-up observation cannot be guaranteed.

Design outcomes

Primary

Measure	Time frame
Lymphocyte subsets;	—

Countries

China

Contacts

Public ContactZhang Cheng

Xinqiao Hospital, Army Military Medical University

1764180534@qq.com+86 13098770350

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026